Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05854433 · ClinicalTrials.gov registry record

Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2

A clinical trial of Myotonic Dystrophy Type 1 and Myotonic Dystrophy Type 2, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT05854433: Recruiting study of Myotonic Dystrophy Type 1 and Myotonic Dystrophy Type 2, sponsored by Wake Forest University Health Sciences.

NCT05854433 is a study of Myotonic Dystrophy Type 1 and Myotonic Dystrophy Type 2 that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 100 participants, below the 1,052-participant average among 3 other Myotonic Dystrophy Type 1 trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05854433, a study of Myotonic Dystrophy Type 1 and Myotonic Dystrophy Type 2, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

Nearly two-third of patients with myotonic dystrophy type 2 (DM2) report that impaired cognition is among the most disabling symptoms and deeply affects their quality of life. Yet, relatively little is known about how DM2 affects brain structure and cognitive function as brain imaging studies in DM2 are extremely limited. This is a prospective, cross-sectional study of brain structure and function on cognitive and motor performance in patients with DM2 \& DM1 compared to healthy controls. All participants will undergo magnetic resonance imaging (MRI) to evaluate brain structure and white matter integrity, a comprehensive battery of cognitive and motor measures, self-reported questionnaires, and blood collection for brain-based biomarker analysis. A subset of participants will undergo lumbar puncture for cerebrospinal fluid (CSF) collection for additional biomarker analysis and validation. This work is critical to inform the development of rigorous clinical trial designs and plan for a longitudinal study to evaluate MRI measures as imaging biomarkers of disease progression and therapeutic response in DM2 \& DM1.

Conditions Studied

Myotonic Dystrophy Type 1 Myotonic Dystrophy Type 2

Interventions

  • OTHER Non-interventional study

Study Locations (1)

North Carolina

  • Wake Forest University Health Sciences - Winston-Salem

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-04-26
Est. Completion 2027-06
Wake Forest University Health Sciences

1,140 total trials

What NCT05854433 shows while recruiting

NCT05854433 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,052-participant average among 3 other Myotonic Dystrophy Type 1 trials with a reported enrollment target (90% lower).

The record links to 2 conditions, with Myotonic Dystrophy Type 1 appearing as the primary indexed condition, and to 1 intervention - of which Non-interventional study is the first listed.

NCT05854433 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT05854433 about?

NCT05854433 is a clinical study titled "Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2". Nearly two-third of patients with myotonic dystrophy type 2 (DM2) report that impaired cognition is among the most disabling symptoms and deeply affects their quality of life. Yet, relatively little is known about how DM2 affects brain structure and cognitive function as brain imaging studies in DM2...

What is the current status of trial NCT05854433?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-04-26. Estimated completion is 2027-06.

What conditions does trial NCT05854433 study?

This clinical trial studies the following conditions: Myotonic Dystrophy Type 1, Myotonic Dystrophy Type 2.

What interventions are being tested in trial NCT05854433?

The interventions under investigation include: Non-interventional study (OTHER).

Who is sponsoring clinical trial NCT05854433?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05854433 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myotonic Dystrophy Type 1

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05854433

Source: ClinicalTrials.gov NCT05854433, the US trial registry maintained by the National Library of Medicine. NCT05854433 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.